Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase
Open accessAbstract
To explore the differences in glucose-lipid metabolism profiles among the 3 TKIs, we designed a retrospective study to compare the onset of hyperglycaemia, hypertriglyceridemia, hypercholesterolemia and hyper-low density lipoprotein (LDL)-cholesterolemia in the patients with normal baseline glucose-lipid profiles and had no medical record of cardio- or cerebro-vascular diseases and/or metabolic syndrome diseases, and identify variables associated with them. 370 chronic myeloid leukaemia patients receiving dasatinib, nilotinib or imatinib therapy ≥3 months were retrospectively reviewed. During TKI-therapy, the mean fasting glucose, triglyceride, cholesterol, and LDL-cholesterol levels increased significantly in both dasatinib and nilotinib cohorts compared with the imatinib cohort. In multivariate analyses, dasatinib was the factor significantly associated with both poor hyperglycaemia- and hypertriglyceridemia-free survival. In addition, nilotinib was significantly associated with more occurrences of hyperglycaemia and hypercholesterolemia; increasing age was significantly associated with more occurrences of hyperglycaemia and hypertriglyceridemia. We concluded that dasatinib, similar to nilotinib, has the adverse impact on glucose-lipid metabolism compared with imatinib.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Dasatinib has been associated with changes in glucose regulation, including both hyperglycemia and hypoglycemia.
“D has been associated with changes in glucose regulation with reports of both hyperglycemia and hypoglycemia emerging45,46.”
From Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial (2023) · cites this paper as [46]
The Results and Discussion report that dasatinib was associated with a higher onset of hyperglycaemia. The Discussion also reports studies in which dasatinib lowered blood glucose or ameliorated hyperglycaemia, but it does not report hypoglycaemia; lowering elevated glucose is not the same as causing low blood glucose. (LLM, conf=0.87)
Experimental — accuracy not yet measuredA prior retrospective study in adults with CML and normal baseline glucose and lipid levels suggested dasatinib may cause mild increases in glucose, triglycerides, and LDL cholesterol.
“A prior retrospective study conducted in adults with CML and normal baseline glucose and lipid levels suggested that D may cause mild increases in glucose, triglycerides and low-density lipoprotein–cholesterol levels46.”
From Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial (2023) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,985 · see citing works
Bower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904 · see citing works
Hochhaus, A., Saglio, G. N., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P. D., Étienne, G., Dorlhiac‐Llacer, P. E., Clark, R. E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.5 · Cited by 836 · see citing works
Cortes, J. E., Kim, D., Pinilla-Ibarz, J. A., le Coutre, P. D., PAQUETTE, R. L., Chuah, C. T. H., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2018) · Blood · doi:10.1182/blood-2016-09-739086 · Cited by 590 · see citing works
for the SAKK and the German CML Study Group, Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S. W., Kolb, H., Neubauer, A., HOSSFELD, D. K., Nerl, C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.253 · Cited by 340 · see citing works
Sasaki, K., Strom, S. S., O'Brien, S. M., Jabbour, E. J., Ravandi, F., Konopleva, M. Y., Borthakur, G. M., Pemmaraju, N., Daver, N. G., Jain, P., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00048-4 · Cited by 328 · see citing works
Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertić, D., Costeas, P., Mayer, J., Indrák, K., Everaus, H., et al. (2015) · Leukemia · doi:10.1038/leu.2015.73 · Cited by 256 · see citing works
Agostino, N. M., Chinchilli, V. M., Lynch, C. J., Koszyk-Szewczyk, A., Gingrich, R., Sivik, J. M., & Drabick, J. J. (2010) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155210378913 · Cited by 156 · see citing works
Réa, D., Mirault, T., Cluzeau, T., Gautier, J., Guilhot, F., Dombret, H., & Messas, E. (2014) · Haematologica · doi:10.3324/haematol.2014.104075 · Cited by 144 · see citing works
Chronic myeloid leukemia in Asia
Au, W. Y., Caguioa, P. B., Chuah, C. T. H., Hsu, S. C., Jootar, S., Kim, D., Kweon, I., O’Neil, W. M., Saikia, T. K., & Wang, J. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0230-0 · Cited by 117 · see citing works
Wang, J., Shen, Z., Saglio, G. N., Jin, J., Huang, H., Hu, Y., Du, X., Li, J., Meng, F., Zhu, H., et al. (2015) · Blood · doi:10.1182/blood-2014-09-601674 · Cited by 107 · see citing works
Self-citationRacil, Z., Rázga, F., Drápalová, J., Burešová, L., Žáčková, D., Palacková, M., Semerád, L., Malášková, L., Haluzı́k, M., & Mayer, J. (2013) · Haematologica · doi:10.3324/haematol.2013.086355 · Cited by 81 · see citing works
Kim, S.-H., Menon, H., Jootar, S., Saikia, T., Kwak, J., Sohn, S. K., Park, J. S., Jeong, S. H., Kim, H., Kim, Y.-K., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.096776 · Cited by 71 · see citing works
Iurlo, A., Orsi, E., Cattaneo, D., Resi, V., Bucelli, C., Orofino, N., Sciumé, M., Elena, C., Grancini, V., Consonni, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5580 · Cited by 67 · see citing works
Breccia, M., Muscaritoli, M., Gentilini, F., Latagliata, R., Carmosino, I., Fanelli, F. R., & Alimena, G. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.01.024 · Cited by 65 · see citing works
Breccia, M., Muscaritoli, M., Cannella, L., Stefanizzi, C., Frustaci, A. M., & Alimena, G. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.01.015 · Cited by 54 · see citing works
Krishnamurthy, M., Ayazi, F., Li, J., Lyttle, A. W., Woods, M., Wu, Y., Yee, S., & Wang, R. (2007) · Endocrinology · doi:10.1210/en.2007-0387 · Cited by 54 · see citing works
Ono, K., Suzushima, H., Watanabe, Y., Kikukawa, Y., Shimomura, T., Furukawa, N., Kawaguchi, T., & Araki, E. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.8314 · Cited by 50 · see citing works
Kim, D., Banavali, S. D., Bunworasate, U., Goh, Y. T., Ganly, P. S., Huang, H., Irving, I., Jootar, S., Goh, H., Koh, L., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.033 · Cited by 44 · see citing works
Gunnarsson, N., Sandin, F., Höglund, M., Stenke, L., Björkholm, M., Lambe, M. P., Olsson‐Strömberg, U., Richter, J., & Själander, A. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12743 · Cited by 38 · see citing works
Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up
Aghel, N., Lipton, J. H., Atenafu, E. G., Kim, D. D. H., & Delgado, D. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.07.006 · Cited by 37 · see citing works
Ross, D. M., Arthur, C., Burbury, K., Ko, B. S., Mills, A. K., Shortt, J., & Kostner, K. (2018) · Internal Medicine Journal · doi:10.1111/imj.13716 · Cited by 26 · see citing works
Agostino, N. M., Chinchilli, V. M., Koszyk-Szewczyk, A., Gingrich, R., Sivik, J. M., & Drabick, J. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.4623 · Cited by 24 · see citing works
Bondon‐Guitton, E., Combret, S., Pérault-Pochat, M.-C., Stève‐Dumont, M., Bagheri, H., Huguet, F., Despas, F., Pathak, A., & Montastruc, J. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0417-x · Cited by 18 · see citing works
Iizuka, K., Niwa, H., Kato, T., & Takeda, J. (2016) · BMJ Case Reports · doi:10.1136/bcr-2015-214284 · Cited by 18 · see citing works
Jiang, Q., Wang, H., Yu, L., & Gale, R. P. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2353-2 · Cited by 17 · see citing works
Self-citationLauseker, M., Gerlach, R., Tauscher, M., & Hasford, J. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2155-y · Cited by 16 · see citing works
Breccia, M., Abruzzese, E., Iurlo, A., Gozzini, A., Isidori, A., Gangemi, D., Pregno, P., & Alimena, G. (2016) · Haematologica · doi:10.3324/haematol.2016.145623 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial
Gonzales, M. M., Garbarino, V. R., Kautz, T. F., Palavicini, J. P., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J. J., Zare, H., Xu, P., Zhang, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02543-w · Cited by 310 · see citing works
Nambiar, A., Kellogg, D., Justice, J., Goros, M., Gelfond, J., Pascual, R., Hashmi, S., Masternak, M., Prata, L., LeBrasseur, N., et al. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104481 · Cited by 298 · see citing works
Diabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187 · see citing works
Associations between Diabetes Mellitus and Selected Cancers
Pliszka, M., & Szablewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137476 · Cited by 52 · see citing works
Nekoukar, Z., Moghimi, M., & Salehifar, E. (2021) · Blood Research · doi:10.5045/br.2021.2021117 · Cited by 44 · see citing works
Cheng, F., Xu, Q., Li, Q., Cui, Z., Li, W., & Zeng, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1113462 · Cited by 47 · see citing works
Caocci, G., Mulas, O., Capodanno, I., Bonifacio, M., Annunziata, M., Galimberti, S., Luciano, L., Tiribelli, M., Martino, B., Castagnetti, F., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-020-04392-w · Cited by 18 · see citing works
Harki, O., Bouyon, S., Sallé, M., Arco-Hierves, A., Lemarié, E., Demory, A., Chirica, C., Vilgrain, I., Pépin, J., Faury, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137012 · Cited by 18 · see citing works
Dasatinib‐induced hypoglycemia in a patient with acute lymphoblastic leukemia
Lundholm, M. D., & Charnogursky, G. A. (2020) · Clinical Case Reports · doi:10.1002/ccr3.2901 · Cited by 9 · see citing works
Janssen, L., Hopman, M. T. E., Swaans, G. J. A., Allard, N. A. E., Boss, M., Lobeek, D., Gotthardt, M., Schirris, T. J. J., Blijlevens, N. M. A., & Timmers, S. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00163.2022 · Cited by 11 · see citing works
Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes
Althubiti, M. (2022) · Saudi Journal of Medicine and Medical Sciences · doi:10.4103/sjmms.sjmms_492_21 · Cited by 11 · see citing works
Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin
Duggan, B. M., Marko, D. M., Muzaffar, R., Chan, D. Y., & Schertzer, J. D. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0212 · Cited by 8 · see citing works
Bhat, M., Saha, P., Narasimhan, M., Shelar, A., Hole, A. R., Krishna, C. M., & Govekar, R. B. (2025) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2025.130771 · Cited by 6 · see citing works
Costa, A. N., Pittorru, R., Caocci, G., Migliore, F., Tona, F., Mulas, O., & Nasa, G. L. (2023) · Hemato · doi:10.3390/hemato4030017 · Cited by 5 · see citing works
Sorafenib decreases glycemia by impairing hepatic glucose metabolism
Ma, J., Sui, F., Liu, Y., Yuan, M., Dang, H., Liu, R., Shi, B., & Hou, P. (2022) · Endocrine · doi:10.1007/s12020-022-03202-9 · Cited by 5 · see citing works
Endocrine Late Effects of Targeted and Immune-Based Therapies in Pediatric Oncology
Ferrari, V. D., Ranieri, A., Ruggi, A., Lanari, M., Melchionda, F., Prete, A., & Baronio, F. (2026) · Cells · doi:10.3390/cells15080676 · Cited by 1 · see citing works
Berra, M., Biro, J., Kashmiri, H., & Daniels, M. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae219 · Cited by 1 · see citing works
García, C. E., & García‐Valverde, A. (2022) · Diabetes práctica · doi:10.52102/diabet/pract/2022.2/art2
Kashiwagi, A. (2022) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/2054
Oral Oncolytics and Cardiovascular Risk Management and Monitoring
White, R. T., Sirek, M. E., & Marrs, J. C. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001458
Brhanie, T. W., & Brhanie, B. W. (2024) · Research Square · doi:10.21203/rs.3.rs-4647921/v1
Khodir, S. A., Sweed, E. M., Kora, M. A. M., Zaki, N. G., Amer, G. S., & Ameen, O. (2025) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2024.2449404
Mugiya, T., Zvandasara, S., Mothibe, M., Ngubane, P., Khathi, A., & Sibiya, N. (2025) · Pharmaceuticals · doi:10.3390/ph18101445
Alshurafa, A., Abdulgayoom, M., Ghasoub, R. S., Mohammed, W. M., Wafi, J., Ali, F. A., & Yassin, M. A. (2026) · Oncology · doi:10.1159/000552769
- Authors
- Yu, L., Liu, J., Huang, X., & Jiang, Q.
- Affiliations
- Peking University People's Hospital (CN)
- Corresponding author
- Jiang, Qian
- Venue
- Scientific Reports
- Published
- 2019-11-26
- Volume
- 9
- Issue
- 1
- Pages
- 17601-17601
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC6879732
- OpenAlex
- W2991565173
- Cited by
- 24
- References
- 28
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 3 · 2020: 1
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81770161)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dasatinib, nilotinib, imatinib, chronic myeloid leukemia, tyrosine kinase inhibitors, glucose-lipid metabolism, hyperglycemia, hypertriglyceridemia, hypercholesterolemia, LDL cholesterol, adverse drug reactions, age as risk factor
- MeSH terms
- Imatinib Mesylate, Dasatinib, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Follow-Up Studies, Glucose, Humans, Hyperglycemia, Cholesterol, LDL, Male, Middle Aged, Neoplasm Proteins, Protein-Tyrosine Kinases, Pyrimidines, Hypertriglyceridemia, Leukemia, Myeloid, Chronic-Phase, Salvage Therapy, Protein Kinase Inhibitors, Lipid Metabolism, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
